دانلود رایگان مقاله لاتین ترومبوسیتوپنی نیولوماب از سایت الزویر
عنوان فارسی مقاله:
تشدید ترومبوسیتوپنی نیولوماب ایمن در یک بیمار مبتلا به سرطان ریه بدون سلول کوچک
عنوان انگلیسی مقاله:
Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer
سال انتشار : 2016
برای دانلود رایگان مقاله ترومبوسیتوپنی نیولوماب اینجا کلیک نمایید.
مقدمه انگلیسی مقاله:
1. Introduction
Nivolumab is a fully human monoclonal IgG4 antibody targeting programmed death-1 (PD-1), a co-inhibitory immune signal receptor expressed in T cells. Based on randomized phase III data demonstrating an overall survival benefit compared to docetaxel [1,2], nivolumab is now approved by the U.S Food and Drug Administration (FDA) for second-line therapy of metastatic nonsmall-cell lung cancer (NSCLC). Immune checkpoint inhibition agents including nivolumab are associated with a unique spectrum of immune-related adverse events (irAEs), most of which are transient but can occasionally be severe or fatal. These have most commonly included dermatologic, gastrointestinal, hepatic, endocrine, and pulmonary inflammatory events, though other organ systems can also be affected. Hematologic irAEs are rare and have mostly been described in melanoma patients treated with ipilimumab [3–6]. Herein we report the case of a NSCLC patient with immune thrombocytopenia (ITP) exacerbated by nivolumab.
برای دانلود رایگان مقاله ترومبوسیتوپنی نیولوماب اینجا کلیک نمایید.
کلمات کلیدی:
Idiopathic thrombocytopenic purpura induced by nivolumab in a ... annonc.oxfordjournals.org/content/27/3/546.full by S Kanameishi - 2016 - Cited by 6 - Related articles Nov 24, 2015 - Idiopathic thrombocytopenic purpura induced by nivolumab in a .... Herein, we report the first case of ITP caused by immune checkpoint ... Toxicities associated with checkpoint inhibitor immunotherapy https://www.uptodate.com/.../toxicities-associated-with-checkpoint-inhibitor-immunot... by M Postow - Cited by 9 - Related articles Nivolumab and pembrolizumab, both of which target PD-1, and atezolizumab and ... of immune-related adverse events (irAEs) caused by checkpoint inhibitors are ...... Hematologic — Red cell aplasia, neutropenia, thrombocytopenia, acquired ... Immune thrombocytopenia exacerbated by nivolumab in a ... - infona.pl https://www.infona.pl/.../bwmeta1.element.elsevier-ad4277b1-642e-363e-930f-527a1... by SJ Bagley - 2016 - Cited by 4 - Related articles Here we report a patient who experienced an exacerbation of underlying immune thrombocytopenia (ITP) while receiving nivolumab for NSCLC. The patient's ... Immunotherapy - Page 172 - Google Books Result https://books.google.com/books?isbn=3319531565 Aung Naing, Joud Hajjar - 2017 - Medical Aung Naing, Joud Hajjar. 64. Bagley SJ, Kosteva JA, Evans TL, Langer CJ. Immune thrombocytopenia exacerbated by nivolumab 65. 66. 67. 68. 69. 70. 71. 72. Bi-cytopenia possibly induced by anti-PD-1 antibody for prim ... journals.lww.com › Home › July 2016 - Volume 95 - Issue 29 by K Inadomi - 2016 - Cited by 2 - Related articles Background: Anti-programmed cell death 1 antibody nivolumab is a ... However, severe anemia and thrombocytopenia appeared in the 6th cycle, and .... Severe bi-cytopenia possibly caused by nivolumab therapy was observed in the present ... Hemophilia A Induced by Ipilimumab - NEJM — www.nejm.org/doi/full/10.1056/NEJMc1110923?viewType=Print Nov 3, 2011 - (2016) Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. Cancer Treatment Communications 6 ... [PDF]Label (PDF) - FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125527s000lbl.pdf OPDIVO (nivolumab) injection, for intravenous use ..... disease exacerbation, pneumonitis, hypercalcemia, pleural effusion, hemoptysis, ... Thrombocytopenia. 14. Searches related to thrombocytopenia exacerbated by nivolumab nivolumab pneumonitis treatment nivolumab toxicity management nivolumab colitis nivolumab adverse events nivolumab rash toxicities of the anti-pd-1 and anti-pd-l1 immune checkpoint antibodies immune related adverse events pembrolizumab toxicity
